Home » Business News » 2014 » November » November 11, 2014

Biofrontera AG hosts conference call on 13 November 2014 to present results of the third quarter 2014

November 11, 2014 - London

Biofrontera AG /Biofrontera AG hosts conference call on 13 November 2014 to present results of the third quarter 2014 . Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

Leverkusen, Germany, 11 November 2014 - Biofrontera AG (FSE/AIM:B8F) will announce Biofrontera Group results for the 1st nine months of the fiscal year on 13 November 2014. The Biofrontera Management will host a conference call to inform about the consolidated financial statements and discuss the recent progress of the Company.
The conference for shareholders and interested investors will start at 9:00 a.m. (MEZ) in German, at 10:30 a.m. (MEZ) in English.

Telephone conference in German:
13 November 2014, 9:00 a.m.
Dial-in number: +49-(0)69 271 340 800
Room number: 73218216#

Telephone conference in English:
13 November 2014, 10:30 a.m.
Dial-in number: +49-(0)69 271 340 801; +44 (0)203 364 5807
Room number: 51595435#

Please dial into the conference 5 minutes earlier to allow a start in time.


Biofrontera AG
Thomas Schaffer                    +49 (0)214 87632 0

Cortent Kommunikation AG
Volker Siegert                       +49 (0)69-5770300-11

Biofrontera AG (AIM/FSE: B8F, ISIN DE0006046113) is a biopharmaceutical company specialising in the development and distribution of dermatological drugs and medical cosmetics for the treatment and care of skin diseases. Biofrontera's main product is Ameluz®, a prescription drug approved for use in Europe for the treatment of mild to moderate Actinic Keratosis (superficial skin cancer) by photodynamic therapy (light therapy). Biofrontera is the first small German pharmaceutical company to receive a centralized approval for a drug developed in-house. The Company is looking to further develop Ameluz® for use in Basal Cell Carcinoma and is currently progressing through regulatory approvals to sell the product in other territories, in particular the largest pharmaceutical market, the USA.

In addition, the Company markets the Belixos® cosmetic series with plant extracts, currently available in cream and liquid formulations which offer nurturing and regenerating effects for people suffering from pruritus, dry skin or chronic ailments such as eczema or psoriasis.

Biofrontera group was founded in 1997 by Prof. Dr. Hermann Lübbert, the CEO, and is headquartered in Leverkusen, Germany.

This press release contains forward-looking statements based on the currently held beliefs and assumptions of the management of Biofrontera AG, which are expressed in good faith and, in their opinion, reasonable. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the assumptions expressed or implied in this press release to be faulty. Given these risks, uncertainties and other factors, recipients of this document are cautioned not to place undue reliance on the forward-looking statements. Biofrontera AG disclaims any obligation to update these forward-looking statements to reflect future events or developments.

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Biofrontera AG via Globenewswire



Comment on this story